# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001104659-25-099565
**Filing Date:** 2025-10
**Character Count:** 12565
**Document Hash:** 736214de137ff1bde86835a8e7d87cc5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-099565.hdr.sgml**: 20251015

**ACCESSION NUMBER**: 0001104659-25-099565

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251015

**DATE AS OF CHANGE**: 20251015

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88910
- **FILM NUMBER:** 251393602

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fairmount Funds Management LLC
- **CENTRAL INDEX KEY:** 0001802528

**ORGANIZATION NAME:**
- **EIN:** 364841215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 267-262-5300

**MAIL ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**Issuer:** Astria Therapeutics, Inc.

**Title of Class of Securities:** Common Stock, par value $0.001 per share

**CUSIP Number:** 04635X102

**Date of Event Which Requires Filing of this Statement:** 10/14/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Fairmount Funds Management LLC | Names of Reporting Persons<br>Fairmount Funds Management LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2377049.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2377049.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2377049.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2377049.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.0% | Percent of Class Represented by Amount in Row (9)<br>4.0% |
| 12. | Type of Reporting Person (See Instructions)<br>IA | Type of Reporting Person (See Instructions)<br>IA |

**Comment for Type of Reporting Person:** The shares reported herein for the Reporting Person represent (i) 650,000 shares of the Issuer's Common Stock Fairmount Healthcare Fund II LP ("Fund II") has the right to acquire through the exercise of 650,000 pre-funded warrants ("Pre-Funded Warrants"), and (ii) 1,727,049 shares of the Issuer's Common Stock Fund II has the right to acquire through the exercise of 1,727,049 common warrants ("Warrants").

Row 13 is based upon 58,811,943 shares of the Issuer's Common Stock outstanding as of October 14, 2025, consisting of (i) 56,434,894 shares of Common Stock outstanding as of July 31, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) 650,000 shares of Common Stock underlying the Pre-Funded Warrants and (iii) 1,727,049 shares of Common Stock underlying the Warrants owned by Fund II.

---

| 1. | Names of Reporting Persons<br>Fairmount Healthcare Fund II GP LLC | Names of Reporting Persons<br>Fairmount Healthcare Fund II GP LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2377049.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2377049.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2377049.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2377049.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.0% | Percent of Class Represented by Amount in Row (9)<br>4.0% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The shares reported herein for the Reporting Person represent (i) 650,000 shares of the Issuer's Common Stock Fund II has the right to acquire through the exercise of 650,000 Pre-Funded Warrants, and (ii) 1,727,049 shares of the Issuer's Common Stock Fund II has the right to acquire through the exercise of 1,727,049 Warrants.

Row 13 is based upon 58,811,943 shares of the Issuer's Common Stock outstanding as of October 14, 2025, consisting of (i) 56,434,894 shares of Common Stock outstanding as of July 31, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) 650,000 shares of Common Stock underlying the Pre-Funded Warrants and (iii) 1,727,049 shares of Common Stock underlying the Warrants owned by Fund II.

---

**Item 1(a). Name of Issuer:**
Astria Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
22 Boston Wharf Road, 10th Floor Boston, MA, 02210

**Item 2(a). Name of Person Filing:**
This Amendment No. 7 to Schedule 13G amends and restates the statements on Schedule 13G originally filed on December 31, 2021, Amendment No. 1 thereto filed on September 22, 2021, Amendment No. 2 thereto filed on June 17, 2021, Amendment No. 3 thereto filed on February 14, 2023, Amendment No. 4 thereto filed on February 14, 2024, Amendment No. 5 thereto filed on November 14, 2024 and Amendment No. 6 thereto filed on February 14, 2025.

(A) Fairmount Funds Management LLC
(B) Fairmount Healthcare Fund II GP LLC

**Item 2(b). Address of Principal Business Office:**
(A) 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428
(B) 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428

**Item 2(c). Citizenship:**
(A) Delaware
(B) Delaware

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.001 per share

**Item 2(e). CUSIP Number:**
04635X102

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

As of October 14, 2025, Fund II holds (i) 650,000 Pre-Funded Warrants with the right to acquire 650,000 shares of Common Stock and (ii) 1,727,049 common warrants ("Warrants", with the right to acquire 1,727,049 shares of Common Stock at an exercise price of $8.025 per share). Pursuant to the terms of the Pre-funded Warrants and the Warrants, the Reporting Person's beneficial ownership limitation is currently 9.99% (the "Beneficial Ownership Limitation"), which prevents the Reporting Persons from exercising the Pre-funded Warrants or Warrants if, after giving effect to such exercise, the Reporting Persons, together with their affiliates, would beneficially own more than 9.99% of the Issuer's outstanding shares of Common Stock.

**(b) Percent of class:**

See the response(s) to Item 11 on the attached cover page(s).

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See the response(s) to Item 5 on the attached cover page(s).

**(ii) Shared power to vote or to direct the vote:**

See the response(s) to Item 6 on the attached cover page(s).

**(iii) Sole power to dispose or to direct the disposition of:**

See the response(s) to Item 7 on the attached cover page(s).

**(iv) Shared power to dispose or to direct the disposition of:**

See the response(s) to Item 8 on the attached cover page(s).

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Fairmount Funds Management LLC**

**Date:** 10/15/2025

**By:** /s/ Peter Harwin

**Name & Title:** Peter Harwin, Managing Member

**Fairmount Healthcare Fund II GP LLC**

**Date:** 10/15/2025

**By:** /s/ Peter Harwin

**Name & Title:** Peter Harwin, Managing Member